Clinical OutcomesIn HPV16-positive subgroup, the overall response rate increased to 62.5% by RECISTv1.1 and 75% by irRECIST, well above the 12-24% typically observed with standard-of-care ICIs.
Clinical TrialsPDS Biotechnology has initiated its Phase 3 VERSATILE-003 study, a pivotal trial designed to evaluate the safety and efficacy of Versamune HPV in combination with pembrolizumab for a specific type of cancer.
Survival RatesPatients who had undetectable HPV16 ctDNA at 3-4 months showed an improved two-year recurrence-free survival rate of 93%, compared to 30% in those with detectable ctDNA.